Investor Relations

Corporate Profile

Cognition Therapeutics is a clinical-stage biopharmaceutical company leveraging our expertise in the σ-2 (sigma-2) receptor to develop innovative, small molecule therapeutics targeting age-related degenerative diseases. Our initial focus is on degenerative diseases of the CNS and retina such as Alzheimer’s disease, dementia with Lewy bodies and dry age-related macular degeneration.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Latest SEC Filings

Form Filing date Description
SC 13G

A statement of beneficial ownership of common stock by certain persons


Additional proxy soliciting materials - definitive


Amended Notice of Exempt Offering of Securities

Scroll to Top